ANNEE 2019

Publié le 14/02/2020 à 10h34 (mis à jour le 14/02/2020 à 14h41)

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE

Andre L, Gallini A, Montastruc F, Coley N, Montastruc JL, Vellas B, Andrieu S, Gardette V ; MAPT/DSA study group. Anticholinergic exposure and cognitive decline in older adults : Effect of anticholinergic exposure definitions in a 3-year analysis of the Multidomain Alzheimer Preventive Trial (MAPT) study. Br J Clin Pharmacol. 2019 ;85:71-99.

Andre L, Gallini A, Montastruc F, Montastruc JL, Piau A, Lapeyre-Mestre M, Gardette V. Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old : a systematic review. Eur J Clin Pharmacol. 2019 ;75:1631-1644.

Bagheri H. Interest of pharmacoepidemiology for the study of anticoagulants. Therapie. 2019 ;74:245-248.

Bataillard M, Beyens MN, Mounier G, Vergnon-Miszczycha D, Bagheri H, Cathebras P. Muscle Damage Due to Fusidic Acid-Statin Interaction : Review of 75 Cases From the French Pharmacovigilance Database and Literature Reports. Am J Ther. 2019 ;26:e375-e379.

Bégaud B, Montastruc JL. Pharmacoepidemiology, the new paradigm of drug evaluation. Therapie. 2019 ;74:167-168.

Berger E, Delpierre C, Despas F, Bertoli S, Bérard E, Bombarde O, Bories P, Sarry A, Laurent G, Récher C, Lamy S. Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization ? Results from a French longitudinal observational study among older patients. BMC Cancer. 2019 ;19:883.

Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR, Bis JC, Brody JA, Floyd JS, Psaty BM, Molokhia M, Lapeyre-Mestre M, Conforti A, Alfirevic A, van Staa T, Pirmohamed M. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clin Pharmacol Ther. 2019 ;106:1353-1361

Clapes V, Rousseau R, Despas F, Montastruc JL, Olivier P. Adverse Drug Reactions Involving Protein Kinase Inhibitors : A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥ 75 years) with Cancer. Pharmaceutical Medicine. 2018 ;33:21-27.

Caudrelier L, Moulis G, Lapeyre-Mestre M, Sailler L, Pugnet G. Validation of giant cell arteritis diagnosis code in the French hospital electronic database. Eur J Intern Med. 2019 ;60:e16-e17.

Compaci G, Conte C, Oberic L, Ysebaert L, Laurent G, Despas F. Sustained degradation of quality of life in a subgroup of lymphoma survivors : a two-year prospective survey. BMC Cancer. 2019 ;19:1178.

Conte C, Vaysse C, Bosco P, Noize P, Fourrier-Reglat A, Despas F, Lapeyre-Mestre M. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology. Therapie. 2019 ;74:279-288.

Conte C, Bourrel R, Despas F, Lapeyre-Mestre M. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas ? A cohort study based on the French health insurance database in the Midi-Pyrénées region. Fundam Clin Pharmacol. 2019 ;33:327-338.

Crickx E, Poullot E, Moulis G, Goulabchand R, Fieschi C, Galicier L, Meignin V, Coppo P, Delarue R, Casasnovas O, Roos-Weil D, de Leval L, Parrens M, Michel M, Dupuis J, Le Bras F, Fataccioli V, Martin-Garcia N, Godeau B, Haïoun C, Gaulard P, Mahévas M. Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. Eur J Haematol. 2019 ;103:35-42.

Dardonville Q, Salguiero E, Rousseau V, Chebane L, Faillie JL, Gautier S, Montastruc JL, Carvajal A, Bagheri H. Drug-induced osteoporosis/osteomalacia : analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol. 2019 ;75:1705-1711.

De Barros S, Vayr F, Despas F, Strumia M, Podevin C, Gauthier M, Delabesse E, Soulat JM, Laurent G, Huguet F, Herin F. The impact of chronic myeloid leukemia on employment : the French prospective study. Ann Hematol. 2019 ;98:615-623.

De Germay S, Rueter M, Montastruc F, Rousseau V, Lapeyre-Mestre M, Montastruc JL. Trends of atropinic (anticholinergic) exposure in the elderly : a 10-year analysis in the French EGB database. Fundam Clin Pharmacol. 2019 ;33:471-478.

Despas F, Rousseau V, Lafaurie M, De Canecaude C, Durrieu G, Bagheri H, Montastruc F, Montastruc JL. Are lipid-lowering drugs associated with a risk of cataract ? A pharmacovigilance study. Fundam Clin Pharmacol. 2019:33 ;695-702.

Dupui M, Micallef J, Lapeyre-Mestre M. Interest of large electronic health care databases in addictovigilance : Lessons from 15 years of pharmacoepidemiological contribution. Therapie. 2019 ;74:307-314.

Duret-Aupy N, Lagarce L, Blouet A, Kettani S, Conte C, Bourneau-Martin D, Drablier G, Umlil A, Briet M. Liver sinusoidal obstruction syndrome associated with trastuzumab emtansine treatment for breast cancer. Therapie. 2019 ;74:675-688.

Durrieu G, Dardonville Q, Clanet M, Montastruc JL. Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab. Fundam Clin Pharmacol. 2019 ;33:125-126.

Ekstrand C, Linder M, Baricault B, Lafaurie M, Sailler L, Lapeyre-Mestre M, Kieler H, Moulis G, Bahmanyar S. Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts. Thromb Res. 2019 ;178:124-131.

Favrelière S, Lafay-Chebassier C, Fauconneau B, Quillet A, Yéléhé-Okouma M, Montastruc F, Pérault-Pochat MC. Illogical association nalmefene and opioids : Analysis in the French pharmacovigilance database.Therapie. 2019 ;79:365-374.

Floyd JS, Bloch KM, Brody JA, Maroteau C, Siddiqui MK, Gregory R, Carr DF, Molokhia M, Liu X, Bis JC, Ahmed A, Liu X, Hallberg P, Yue QY, Magnusson PKE, Brisson D, Wiggins KL, Morrison AC, Khoury E, McKeigue P, Stricker BH, Lapeyre-Mestre M, Heckbert SR, Gallagher AM, Chinoy H, Gibbs RA, Bondon-Guitton E, Tracy R, Boerwinkle E, Gaudet D, Conforti A, van Staa T, Sitlani CM, Rice KM, Maitland-van der Zee AH, Wadelius M, Morris AP, Pirmohamed M, Palmer CAN, Psaty BM, Alfirevic A ; PREDICTION-ADR Consortium and EUDRAGENE. Pharmacogenomics of statin-related myopathy : Meta-analysis of rare variants from whole-exome sequencing. PLoS One. 2019 ;14:e0218115.

Humbert X, Fedrizzi S, Chrétien B, Sassier M, Bagheri H, Combret S, Drici MD, Le Bas F, Puddu PE, Alexandre J. Hypertension induced by serotonin reuptake inhibitors : Analysis of two pharmacovigilance databases. Fundam Clin Pharmacol. 2019 ;33:296-302.

Kaguelidou F, Durrieu G, Clavenna A. Pharmacoepidemiological research for the development and evaluation of drugs in pediatrics. Therapie. 2019 ;74:315-324.

Koffi KG, Silué DA, Laurent C, Boidy K, Koui S, Compaci G, Adeba ZH, Kamara I, Botty RP, Bognini AS, Sanogo I, Despas F, Laurent G. AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast : a prospective randomized study. BMC Cancer. 2019 ;19:1247.

Lacroix C, Kheloufi F, Montastruc F, Bennis Y, Pizzoglio V, Micallef J. Serious central nervous system side effects of cephalosporins : A national analysis of serious reports registered in the French Pharmacovigilance Database. J Neurol Sci. 2019 ;398:196-201.

Lafaurie M, Montastruc F. Interest of a pharmacovigilance medical consultation : Example of metformin-induced-vitamin B12 deficiency. Presse Med. 2019 ;48:1216-1221.

Lapeyre-Mestre M. Benzodiazepines, cognitive decline and dementia : A review of causality criteria from published observational studies. Therapie. 2019 ;74:407-419.

Lapeyre-Mestre M, Montastruc F. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs. Thérapie. 2019 ;74:209-2014.

Mahevas M, Van Eeckhoudt S, Moulis G, Limal N, Languille L, Bierling P, Dossier A, Duriez F, Galicier L, Morin AS, Tamburini J, Chaoui D, Bouscary D, Jijakli AAL, Khellaf M, Vaida I, Michel M, Vercellino L, Jaddi H, Yollant A, Dosquet C, Godeau B, Chomienne C. Autologous111 Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists. Br J Haematol. 2019 ;186:e44-e47.

Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B ; NS-Park/F-CRIN Network study group. Descriptive analysis of the French NS-Park registry : Towards a nation-wide Parkinson’s disease cohort ? Parkinsonism Relat Disord. 2019 ;64:226-234.

Mines ML, Pacheco T, Castel-Lacana E, de Boissezon X, Marque P, Montastruc F. Venous thrombosis after botulinum therapy in lower limb : A case report and literature review. Ann Phys Rehabil Med. 2019 ;62:457-458.

Montastruc F, Nie R, Loo S, Rej S, Dell’Aniello S, Micallef J, Suissa S, Renoux C. Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. JAMA Psychiatry. 2019 ;76:409-417.

Montastruc F, Renoux C, Dell’Aniello S, Simon TA, Azoulay L, Hudson M, Suissa S. Abatacept initiation in rheumatoid arthritis and the risk of cancer : a population-based comparative cohort study. Rheumatology (Oxford). 2019 ;48:1053-1058.

Montastruc F, Khosrow-Khavar F, Sommet A, Renoux C, Montastruc JL. Tamoxifen administration and the risk of Parkinsonism. Eur J Clin Pharmacol. 2019 ;75:135-136.

Montastruc F, Benevent J, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Risk of Diabetes with Fibrates and Statins : a pharmacoepidemiological study in Vigibase®. Fundam Clin Pharmacol. 2018 ;33:108-112.

Montastruc JL, Benevent J, Montastruc F, Bagheri H, Despas F, Lapeyre-Mestre M, Sommet A. What is pharmacoepidemiology ? Definition, methods, interest and clinical applications. Therapie. 2019 ;74:169-174.

Montastruc JL, Montastruc F, Benevent J, Durrieu G, du Plantier JM, Bagheri H, Sommet A, Damase-Michel C. Tintin in the land of drugs : a pharmacological, pharmacovigilance approach. Therapie. 2019 ; 74:445-447.

Mounié M, Pugnet G, Savy N, Lapeyre-Mestre M, Molinier L, Costa N. Additional costs of polymyalgia rheumatica with giant-cell arteritis. Arthritis Care Res (Hoboken). 2019 ;71:1127-1131.

Nguyen KD, Nguyen HA, Vu DH, Le TT, Nguyen HA Jr, Dang BV, Nguyen TN, Nguyen DH, Nguyen TB, Montastruc JL, Bagheri H. Drug-Induced Anaphylaxis in a Vietnamese Pharmacovigilance Database : Trends and Specific Signals from a Disproportionality Analysis. Drug Saf. 2018 ;42:671-682.

Nguyen KD, Tran TN, Nguyen MT, Nguyen HA, Nguyen HA Jr, Vu DH, Nguyen VD, Bagheri H. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database : A subgroup approach to disproportionality analysis. J Clin Pharm Ther. 2019 ;44:69-77.

Nicol C, Moulis F, Bondon-Guitton E, Durrieu G, Montastruc JL, Bagheri H. Does spontaneous adverse drug reactions’ reporting differ between different reporters ? A study in Toulouse Pharmacovigilance Centre. Therapie. 2019 ;5:521-525.

Petitpain N, Devos D, Bagheri H, Rocher F, Gouraud A, Masmoudi K, Coquerel A. Is TNF inhibitor exposure a risk factor foramyotrophic lateral sclerosis ? Fundam Clin Pharmacol. 2019 ;33:689-694.

Peyro-Saint-Paul L, Besnier P, Demessine L, Biour M, Hillaire-Buys D, de Canecaude C, Fedrizzi S, Parienti JJ. Cushing’s syndrome due to interaction between ritonavir or cobicistat and corticosteroids : a case-control study in the French Pharmacovigilance Database. J Antimicrob Chemother. 2019 ;74:3291-3294.

Sabatier P, Amar J, Montastruc F, Rousseau V, Chebane L, Bouhanick B, Montastruc JL. Breast cancer and spironolactone : an observational postmarketing study. Eur J Clin Pharmacol. 2019 ;75:1593-98.

Sommet A, Pariente A. Methods in pharmacoepidemiology. Therapie. 2019 ;74:187-197.

Sommet A. Interest of pharmacoepidemiology for the study of antibiotic drugs. Therapie. 2019 ;74:249-253.

Sommet A, Bénévent J, Rousseau V, Chebane L, Douros A, Montastruc JL, Montastruc F. What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm ? A Case/Non-case Study in VigiBase®. J Gen Intern Med. 2019 ;34:502-503.

Tournier M, Montastruc F. Interest of pharmacoepidemiology for the study of psychotropic drugs. Therapie. 2019 ;74:239-244.

Tranchard F, Gauthier J, Hein C, Lacombe J, Brett K, Villars H, Sallerin B, Montastruc JL, Despas F. Drug identification by the patient : Perception of patients, physicians and pharmacists.Therapie. 2019 ;74:591-598.

Walburg V, Rueter M, Lamy S, Compaci G, Lapeyre-Mestre M, Laurent G, Despas F. Fear of cancer recurrence in Non- and Hodgkin lymphoma survivors during their first three years of survivorship among French patients. Psychol Health Med. 2019 ;24:1-7.

Ysebaert L, Larcher M, Compaci G, Oberic L, Sahnes L, Banos A, Araujo C, Sommet A, Laurent G, Despas F. Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy : results of the randomized FORTIS study in chronic lymphocytic leukemia. Ann Hematol. 2019 ;98:931-939.

Watson S, Durrieu G. Midostaurin, photosensitivity reaction. WHO U M C, 2019:1-7.

PHARMACOLOGIE CLINIQUE

Arribarat G, Pasternak O, De Barros A, Galitzky M, Rascol O, Péran P. Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson’s disease. Parkinsonism Relat Disord. 2019 ;65:146-152.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:827-833.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Lechat et al. Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:13553-1354.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Nicolas. Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:961-963.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Castello‑Bridoux et al. Comment on Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:973-975.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Coste et al. “Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ?” Clinical Pharmacokinetics. 2019 ;58:967-968.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Author’s Reply to Trechot. Comment on Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:979-980.

Corvol JC, Durif F, Meissner WG, Azulay JP, Haddad R, Guimarães-Costa R, Mariani LL, Cormier-Dequaire F, Thalamas C, Galitzky M, Boraud T, Debilly B, Eusebio A, Houot M, Dellapina E, Chaigneau V, Salis A, Lacomblez L, Benel L, Rascol O ; French NS-Park/F-CRIN Network. Naftazone in advanced Parkinson’s disease : An acute L-DOPA challenge randomized controlled trial. Parkinsonism Relat Disord. 2019 ;60:51-56.

Coutens B, Mouledous L, Stella M, Rampon C, Lapeyre-Mestre M, Roussin A, Guiard BP, Jouanjus E. Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse. Psychopharmacology (Berl). 2019 ;236:2069-2082.

Delamarre A, Tison F, Li Q, Galitzky M, Rascol O, Bezard E, Meissner WG. Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease. J Neural Transm (Vienna). 2019 ;126:789-793.

Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, Kas A, Salabert AS, Ory-Magne F, Payoux P, Brefel-Courbon C. Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson’s disease : a correlation study. J Neural Transm (Vienna). 2019 ;126:279-287.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients : a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol. 2019 ;26:953-960.

Gollion C, Dupouy J, Roberts M, Simonetta-Moreau M, Brefel Courbon C, Rascol O, Honnorat J, Magne FO. Reversible myoclonus-ataxia encephalitis related to anti-mGLUR1 autoantibodies. Mov Disord. 2019 ;34:438-439.

Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson’s disease patients with OFF periods : A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2019 ;71:4-10.

Knudsen K, Krack P, Tonder L, Houeto JL, Rau J, Schade-Brittinger C, Hartmann A, Hälbig TD, Paschen S, Barbe MT, Kühn A, Fraix V, Brefel-Courbon C, Vesper J, Maltête D, Sixel-Döring F, Weiss D, Witjas T, Thobois S, Agid Y, Schnitzler A, Schuepbach WMM, Timmermann L, Damier P, Vidailhet M, Deuschl G ; EARLYSTIM study group. Programming parameters of subthalamic deep brain stimulators in Parkinson’s disease from a controlled trial. Parkinsonism Relat Disord. 2019 ;65:217-223.

Lee PC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Brice A, Vidailhet M, Corvol JC, Elbaz A ; DIGPD Study Group. Examining the Reserve Hypothesis in Parkinson’s Disease : A Longitudinal Study. Mov Disord. 2019 ;34:1663-1671.

Lees A, Ferreira JJ, Rocha JF, Rascol O, Poewe W, Gama H, Soares-da-Silva P. Safety Profile of Opicapone in the Management of Parkinson’s Disease. J Parkinsons Dis. 2019 ;9:733-740.

Magnin A, Iversen VC, Calvo G, Čečetková B, Dale O, Demlova R, Blasko G, Keane F, Kovacs GL, Levy-Marchal C, Monteiro EC, Palmisano L, Pella D, Portolés Pérez A, Rascol O, Schmid C, Tay F, von der Leyen H, Ohmann C. European survey on national training activities in clinical research. Trials. 2019 ;20:616.

Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, Durif F, Brefel-Courbon C. How to diagnose parkinsonian central pain ? Parkinsonism Relat Disord. 2019 ;64:50-53.

Marques A, Vidal T, Pereira B, Benchetrit E, Socha J, Pineau F, Elbaz A, Artaud F, Mangone G, You H, Cormier F, Galitstky M, Pomies E, Rascol O, Derkinderen P, Weintraub D, Corvol JC, Durif F ; DIGPD study group. French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale (QUIP-RS). Parkinsonism Relat Disord. 2019 ;63:117-123.

Meissner WG, Fernagut PO, Dehay B, Péran P, Traon AP, Foubert-Samier A, Lopez Cuina M, Bezard E, Tison F, Rascol O. Multiple System Atrophy : Recent Developments and Future Perspectives. Mov Disord. 2019 ;34:1629-1642.

Mouly S, Roustit M, Bagheri H, Perault-Pochat MC, Molimard M, Bordet R. The French Levothyrox® crisis : We did the best we could but…. Therapie. 2019 ;74:431-435.

Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. Expert Opin Pharmacother. 2019 ;20:635-645.

Rascol O. CVT-301 for Parkinson’s disease : dose and effect size issues. Lancet Neurol. 2019 ;18:128-130.

Revel-Mouroz P, Viguier A, Cazzola V, Calviere L, Patsoura S, Rousseau V, Sommet A, Albucher JF, Cognard C, Olivot JM, Bonneville F, Raposo N. Acute ischaemic lesions are associated with cortical superficial siderosis in spontaneous intracerebral hemorrhage. Eur J Neurol. 2019 ;26:660-666.

Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G ; EARLYSTIM study group. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology. 2019 ;92:e1109-e1120.

Taib S, Ory-Magne F, Brefel-Courbon C, Moreau Y, Thalamas C, Arbus C, Simonetta-Moreau M. Repetitive transcranial magnetic stimulation for functional tremor : A randomized, double-blind, controlled study. Mov Disord. 2019 ;34:1210-1219.

Truffert E, Fournier Charrière E, Treluyer JM, Blanchet C, Cohen R, Gardini B, Haas H, Liard F, Montastruc JL, Nicollas R, Pondaven S, Stahl JP, Wood C, Couloigner V. Guidelines of the French Society of Otorhinolaryngology (SFORL) : Nonsteroidal anti-inflammatory drugs (NSAIDs) and pediatric ENT infections. Short version. Eur Ann Otorhinolaryngol Head Neck Dis. 2019 ;136:289-294.

Vardon Bounes F, Pichon X, Ducos G, Ruiz J, Samier C, Silva S, Sommet A, Fourcade O, Conil JM, Minville V. Remifentanil for Procedural Sedation and Analgesia in Central Venous Catheter Insertion : A Randomized, Controlled Trial. Clin J Pain. 2019 ;35:691-695.

Vergnet S, Hives F, Foubert-Samier A, Payoux P, Fernandez P, Meyer M, Dupouy J, Brefel-Courbon C, Ory-Magne F, Rascol O, Tison F, Pavy-Le Traon A, Meissner WG. Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. Parkinsonism Relat Disord. 2019 ;63:199-203.

PHARMACOLOGIE DE LA REPRODUCTION

Araujo M, Hurault-Delarue C, Bouilhac C, Petiot D, Benevent J, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C, Lacroix I. Non-Steroidal Anti-Inflammatory Drug (NSAID) Prescriptions from the 6th Month of Pregnancy : Impact of Advice from Health Authorities. Fundam Clin Pharmacol. 2019 ;33:581-588.

Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I, Damase-Michel C. POMME : The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure. Drug Saf. 2019 ;42:45-54.

Benevent J, Hurault-Delarue C, Araujo M, Montastruc F, Montastruc JL, Lacroix I, Damase-Michel C. Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties. Fundam Clin Pharmacol. 2018 ;33:314-326.

Benevent J, Lacroix I. Medication and pregnancy, asssessing the risk-benefit balance. Actualités pharmaceutiques. 2019 ;588:21-27.

Benevent J, Araujo M, Hurault-Delarue C, Montastruc JL, Sommet A, Lacroix I, Damase-Michel C. Pharmacoepidemiology in pregnancy. Therapie. 2019 ;74:289-300.

Baudou E, Benevent J, Montastruc JL, Touati G, Hachon Le Camus C. Adverse Effects of Treatment with Valproic Acid during the Neonatal Period. Neuropediatrics. 2019 ;50:31-40.

Charlton R, Damase-Michel C, Hurault-Delarue C, Gini R, Loane M, Pierini A, Puccini A, Neville A, Snowball J, Morris JK ; EUROmediSAFE consortium. Did advice on the prescription of sodium valproate reduce prescriptions to women ? An observational study in three European countries between 2007 and 2016. Pharmacoepidemiol. Drug Saf. 2019 ;28:1519-1528.

Hurault-Delarue C, Morris JK, Charlton R, Gini R, Loane M, Pierini A, Puccini A, Neville A, Snowball J, Damase-Michel C ; EUROmediSAFE consortium. Prescription of antiepileptic medicines including valproate in pregnant women : A study in three European countries. Pharmacoepidemiol Drug Saf. 2019 ;28:1510-1518.

Hurault-Delarue C, Lacroix I, Bénard-Laribière A, Montastruc JL, Pariente A, Damase-Michel C. Antidepressants during pregnancy : a French drug utilisation study in EFEMERIS cohort. Eur Arch Psychiatry Clin Neurosci. 2019 ;841-849.

ADDICTOVIGILANCE

Auffret M, Rolland B, Béhal H, Labreuche J, Jouanjus E, Bordet R, Gautier S. A capture-recapture method for estimating theincidence of off-label prescriptions : the example of baclofen for alcohol use disorder in France. Therapies. 2019 ;74:645-650.

Cantagrel N, Lestrade C, Roussin A. Differing Perception of Attachment to Analgesic Treatment between Pain Specialist and Patient. Douleur analg. 2019 ;32:105-107.

Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse : Results of a population-based cohort study in France. Br J Clin Pharmacol. 2019 ;6:1260-1269.

Jouanjus E, Lapeyre-Mestre M, Nodot M, Roussin A, Franchitto N, Boyes JP, Nasr N, Oustric S, Dupouy J. Teaching Basic Knowledge on Substance Use Disorders : the Impact of e-Learning on Health Professionals. Clin Ther. 2019 ;41:2154-2161.

Jouanjus E, Micallef J, Mallaret M, Lapeyre-Mestre M. Comment on : An Insight Into Z-Drug Abuse and Dependence : An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. Int J Neuropsychopharmacol. 2019 ;22:528-530.

Jouanjus E, Goyal H. Editorial commentary : Cardiovascular complications of cannabis use. Trends Cardiovasc Med. 2019 ;29:408-409.

Micallef J, Jouanjus E, Mallaret M, Lapeyre Mestre M. Safety signal detection by the French Addictovigilance Network : Innovativemethods of investigation, examples and usefulness for public health.Therapie. 2019 ;74:579-590.

Ponté C, Giron A, Crequy M, Lapeyre-Mestre M, Fabre N, Salles J. Cluster Headache in Subjects With Substance Use Disorder : A Case Series and a Review of the Literature. Headache. 2019 ;59:576-589.

Roussin A, Roche G, Delage N, Chenaf C, Cantagrel N, Authier N. Réseau français des centres d’addictovigilance. Weak Opioids Withdrawal Strategies : a Comparative Study between Pain and Addiction Physicians. Douleur analg. 2019 ;32:99-104.

PHARMACOLOGIE FONDAMENTALE

Besnier F, Labrunée M, Richard L, Faggianelli F, Kerros H, Soukarié L, Bousquet M, Garcia JL, Pathak A, Gales C, Guiraud T, Sénard JM. Short-term effects of a 3-week interval training program on heart rate variability in chronic heart failure. A randomised controlled trial.Ann Phys Rehabil Med. 2019 ;62:321-328.

Blanc C, Viguier A, Calviere L, Planton M, Albucher JF, Rousseau V, Sommet A, Bonneville F, Pariente J, Olivot JM, Raposo JN. Underlying small vessel disease associated with mixed cerebral microbleeds. Front Neurol. 2019 ;10:1126.

Franchini DM, Lanvin O, Tosolini M, Patras de Campaigno E, Cammas A, Péricart S, Scarlata CM, Lebras M, Rossi C, Ligat L, Pont F, Arimondo PB, Laurent C, Ayyoub M, Despas F, Lapeyre-Mestre M, Millevoi S, Fournié JJ. Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Rep. 2019 ;26:94-107.

Garcia C, Maurel-Ribes A, Nauze M, N’Guyen D, Martinez LO, Payrastre B, Sénard JM, Galés C, Pons V. Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y12 receptor. Cell Mol Life Sci. 2019 ;76:561-576.

Guilbeau-Frugier C, Cauquil M, Karsenty C, Lairez O, Dambrin C, Payré B, Cassard H, Josse C, Seguelas MH, Allart S, Branchereau M, Heymes C, Mandel F, Delisle MB, Pathak A, Dague E, Sénard JM, Galés C. Structural evidence for a new elaborate 3D-organization of the cardiomyocyte lateral membrane in adult mammalian cardiac tissues. Cardiovasc Res. 2019 ;115:1078-1091.

Kermorgant M, Ben Salem J, Santelli J, Calise D, Oster AC, Lairez O, Coudret C, Verelst M, Gales C, Sénard JM, Beaudry F, Pavy-Le Traon A, Roux C, Mauricot R, Arvanitis DN. Evaluation of upconverting nanoparticles towards heart theranostics. PLoS One. 2019 ;14:e0225729.

Kermorgant M, Nasr N, Custaud MA, Navasiolava N, Arbeille P, Guinet P, Labrunée M, Besnier F, Arvanitis DN, Czosnyka M, Senard JM, Pavy-Le Traon A. Effects of Resistance Exercise and Nutritional Supplementation on Dynamic Cerebral Autoregulation in Head-Down Bed Rest. Front Physiol. 2019 ;10:1114.